Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease

Current Drug Targets

Volumn 15, Issue 7, 2014, Pages 703-709

  Donate Correa, Javier ^a,b   Domínguez Pimentel, Virginia ^a   Muros de Fuentes, Mercedes ^a,b   Mora Fernández, Carmen ^a,b   Martín Núñez, Ernesto ^a   Cazaña Pérez, Violeta ^a   Navarro González, Juan F ^a,b  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b GEENDIAB Grupo Español para el Estudio de la Nefropatía Diabética REDINREN RD12 0021 0019   (Spain)

Author keywords

Cardiovascular disease; Inflammation; Paricalcitol; Vitamin D analogues; Vitamin D receptor

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 4; C REACTIVE PROTEIN; CALCIUM; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; RETINOID X RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ERGOCALCIFEROL;

ALBUMINURIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLISM; MORBIDITY; MORTALITY; NONHUMAN; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; HYPERPARATHYROIDISM; HYPOCALCEMIA; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; ERGOCALCIFEROLS; HUMANS; HYPERPARATHYROIDISM; HYPOCALCEMIA; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME; VITAMIN D;

EID: 84904468884     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140417120902     Document Type: Article

References (83)

1. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999; 73: 14-9.
2. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43.
3. Canalejo R, Canalejo A, Martinez-Moreno JM, et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 2010; 21: 1125-35.
4. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004; 80: 1678-88.
5. Holick MF. Vitamin D for health and in chronic kidney disease. Semin Dial 2005; 18: 266-75.
6. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med 1999; 340: 115-26.
7. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8: 174-9.
8. Shvil Y, Naveh-Many T, Barach P, et al. Regulation of parathyroid cell gene expression in experimental uremia. J Am Soc Nephrol 1990; 1: 99-104.
9. Szabo A, Merke J, Beier E, et al. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1049-56.
10. Silver J, Russell J, Sherwood LM, et al. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 1985; 82: 4270-73.
11. Wu-Wong JR. Vitamin D receptor: a highly versatile nuclear receptor. Kidney Int 2007; 72: 237-9.
12. Yang L, Ma J, Zhang X, et al. Protective role of the vitamin D receptor. Cell Immunol 2012; 279: 160-6.
13. Nemere I, Garbi N, Hämmerling GJ, et al. Intestinal cell calcium uptake and the targeted knockout of the 1,25D3-MARRS (membrane-associated, rapid response steroid-binding) receptor/ PDIA3/Erp57. J Biol Chem 2010; 285: 31859-66.
14. Nemere I, Garcia-Garbi N, Hämmerling GJ, et al. Intestinal cell phosphate uptake and the targeted knockout of the 1,25D3-MARRS receptor/PDIA3/ERp57. Endocrinology 2012; 153: 1609-15.
15. Carrillo-López N, Alvarez-Hernández D, González-Suárez I, et al. Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol Dial Transplant 2008; 23: 3479-84.
16. Patel SR, Ke HQ, Vanholder R, et al. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995; 96: 50-9.
17. Canaff L, Hendy GN. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002; 277: 30337-50.
18. Kifor O, MacLeod RJ, Diaz R, et al. Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR transfected HEK293 cells. Am J Physiol Renal Physiol 2001; 280: 291-302.
19. Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-40.
20. Denda M, Finch J, Slatopolsky E. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996; 28: 596-602.
21. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117: 4003-8.
22. Russell J, Lettieri D, Sherwood LM. Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986; 119: 2864-66.
23. Martin KJ, González EA, Gellens M, et al. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-32.
24. Hervás-Sánchez JG, Prados Garrido MD, Polo Moyano A, et al. Effectiveness of treatment with oral paricalcitol in patients with pre-dialysis chronic kidney disease. Nefrologia 2011; 31: 697-706.
25. Finch JL, Brown AJ, Slatopolsky E. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999; 10: 980-5.
26. Nakane M, Fey TA, Dixon DB, et al. Differential effects of Vitamin D analogs on bone formation and resorption. Steroid Biochem Mol Biol 2006; 98: 72-7.
27. Hirata M, Endo K, Ohkawa H, et al. A comparison between daily and thrice-weekly i.v. administration of 1,25-dihydroxy-22-oxavitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action in uraemic rats. Nephrol Dial Transplant 2002; 10: 37-40
28. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56.
29. Sprague SM, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-90.
30. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-65.
31. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-25.
32. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-13.
33. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-80.
34. Cozzolino M, Brancaccio D, Cannella G, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012; 27: 3588-94.
35. Shoji T, Shinohara K, Kimoto E, et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-84.
36. Hansen D, Rasmussen K, Danielsen H, et al. No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial. Kidney Int 2011; 80: 841-50.
37. Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67: 1999-2012.
38. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-17.
39. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-18.
40. Cardús A, Panizo S, Parisi E, et al. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-6.
41. Hirata M, Katsumata K, Endo K, et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transplant 2003; 18: 1770-6.
42. Noonan W, Koch K, Nakane M, et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 2008; 23: 3824-30.
43. Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 2012; 27: 3270-8
44. Coyne DW, Andress DL, Amdahl MJ, et al. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant 2013; 28: 2260-8.
45. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-11.
46. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340-9.
47. Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010; 65: 225-36.
48. McGonigle RJ, Timmis AD, Keenan J, et al. The influence of 1 alpha-hydroxycholecalciferol on left ventricular function in endstage renal failure. Proc Eur Dial Transplant Assoc 1981; 18: 579-85.
49. Kim HW, Park CW, Shin YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006; 102: 21-9.
50. Park CW, Oh YS, Shin YS, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
51. Panizo S, Barrio-Vázquez S, Naves-Díaz M, et al. Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis. Nephrol Dial Transplant 2013; 28: 2735-44.
52. Wang AY, Fang F, Chan J, et al. Effect of Paricalcitol on Left Ventricular Mass and Function in CKD--The OPERA Trial. J Am Soc Nephrol 2013. In press.
53. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012 15; 307:674-84.
54. Cardús A, Parisi E, Gallego C, et al. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006; 69: 1377-84.
55. Cardus A, Panizo S, Encinas M, et al. 1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009; 204: 85-9.
56. Panizo S, Cardus A, Encinas M, et al. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 2009; 104: 1041-8.
57. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 229-38.
58. Fryer RM, Rakestraw PA, Nakane M, et al. Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 2007; 106: 76-81.
59. Freundlich M, Li YC, Quiroz Y, et al. Paricalcitol Downregulates Myocardial Renin-Angiotensin and Fibroblast Growth Factor Expression and Attenuates Cardiac Hypertrophy in Uremic Rats. Am J Hypertens. 2014; 27(5): 720-6.
60. Lo WK. Serum parameters, inflammation, renal function and patient outcome. Contrib Nephrol 2006; 150: 152-5.
61. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-30.
62. Helming L, Böse J, Ehrchen J, et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106: 4351-8.
63. Navarro-González JF, Mora-Fernández C, Muros M, et al. Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol 2009; 4: 1646-54.
64. Wanner C, Zimmermann J, Schwedler S, et al. Inflammation and cardiovascular risk in dialysis patients. Kidney Int Suppl 2002; 80: 99-102.
65. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 787-96.
66. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249-55.
67. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch Biochem Biophys 2000; 374: 334.
68. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164: 2405-11.
69. Yu XP, Mocharla H, Hustmyer FG, et al. Vitamin D receptor expression in human lymphocytes: signal requirements and characterization by Western blots and DNA sequencing. J Biol Chem 1991; 266: 7588.
70. Hewison M, Freeman L, Hughes SV, et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 2003; 170: 5382-90.
71. Kizaki M, Norman AW, Bishop JE, et al. 1,25-Dihydroxyvitamin D3 receptor RNA: expression in hematopoietic cells. Blood 1991; 77: 1238-47.
72. Seibert E, Levin NW, Kuhlmann MK. Immunomodulating effects of vitamin D analogs in hemodialysis patients. Hemodial Int 2005; 9: 25-9.
73. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93-101.
74. Bacchetta JL, Sea JL, Chun RF, et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes. Bone Miner Res 2013; 28: 46-55
75. Elefhteriadis T, Antoniadi G, Liaopoulos V, et al. Inverse association of serum 25-hydroxivitamin D with markers of inflammation and suppression of osteoclastic activity in hemodialysis patients. Iran J Kidney Dis 2012; 6: 129-35.
76. Müller K, Haahr PM, Diamant M, et al. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992; 4: 506-12.
77. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NFkappaB signalling. J Am Soc Nephrol 2008; 19: 1741-52.
78. Moe SM, Zekonis M, Harezlak J, et al. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 2001; 38: 792-802.
79. Sochorová K, Budinsk- V, Rozková D, et al. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol 2009; 133: 69-77.
80. Izquierdo MJ, Cavia M, Muñiz P, et al. Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol 2012; 13: 159.
81. Navarro-González JF, Donate-Correa J, Méndez ML, et al. Antiinflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study. J Clin Pharmacol 2013; 53: 421-6.
82. Donate-Correa J, Domínguez-Pimentel V, Méndez-Pérez ML, et al. Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease. Mediators Inflamm 2014; 2014: 670475.
83. Guerrero F, Montes de Oca A, Aguilera-Tejero E, et al. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012; 27: 2206-12.